AlphAIalphai — Financial news for AI agents
GlobeNewswireMAY 53 min read$HBIO

Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET

HOLLISTON, Mass., May 05, 2025 ( GLOBE NEWSWIRE ) -- Harvard Bioscience, Inc. ( Nasdaq: HBIO ) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Original reporting
GlobeNewswire · Harvard Bioscience, Inc.
Published May 5, 2025, 8:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 5, 2025, 9:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET — source image
Source · www.globenewswire.com
Decision brief

The 30-second read

$HBIOBullishMed
01

Why it matters

Earnings results could influence investor confidence and sector sentiment, affecting stock performance.

02

Market read

The upcoming earnings call is a significant event for traders focusing on biotech and life sciences sectors, with potential for short-term trading opportunities.

03

What to watch

Market-wide macroeconomic conditions and sector-specific news could overshadow earnings impact.

Timing: High, as the earnings call is scheduled for May 12, 2025, at 8:00 AM ET.

Background

Harvard Bioscience specializes in scientific research tools and devices, with upcoming earnings expected to reflect recent operational performance.

Company-level read

Ticker impact

$HBIOBullishMedium confidence
Context

Primary focus due to scheduled earnings report.

Expected impact

Moderate upward movement expected post-earnings if results are favorable; potential short-term volatility.

Evidence & confidence

Earnings reports often influence stock prices; current sentiment suggests cautious optimism, but actual results will determine the magnitude.

Market effects

Sector

Potential positive impact on the Life Sciences sector if earnings surpass expectations.

Regional

Limited regional impact; primarily relevant to US markets.

Global

Moderate, as Harvard Bioscience operates within the global biotech industry.

Counterpoint

What could challenge this read

Results may fall short of expectations, leading to a short-term decline in stock price.

Key entities

  • Company
    Harvard Bioscience, Inc.

    A biotech equipment manufacturer scheduled to report Q1 2025 earnings.

Read at source← All news

Related articles

AUG 18
$HBIOMedAI 8/10

Harvard Bioscience (HBIO) Q2 2026 Earnings Call Transcript

Harvard Bioscience (HBIO) reported Q2 2026 revenue of $22.7M, up 11%, and adjusted EBITDA of $1.7M, up 11%. Full-year revenue guidance was raised to 3-5% growth, but gross margin guidance was lowered to 57-59% due to product and geographic mix shifts. The company expects $3M in cost savings from Project Viking in 2027. Americas and APAC regions showed strong growth, while Europe grew modestly. Adjusted EPS was -$0.14, and Q3 revenue guidance is $21.0M-$22.6M.

fool.com6 min
AUG 13
$HBIOMed

Harvard Bioscience, Inc. Q2 2026 Earnings Call Summary

Harvard Bioscience (HBIO) reported Q2 2026 revenue up 11%, driven by CRO demand and double-digit growth in telemetry and CMT portfolios. China sales rose on its “Made in China” BTX line. Recurring revenue reached 55%. Full-year guidance raised to 3% to 5% growth, but adjusted gross margin cut 100 bps to 57% to 59%, with Project Viking cost savings.

yahoo.com6 min
AUG 11
$HBIOMed

HARVARD BIOSCIENCE INC (HBIO): Results of Operations and Financial Condition

HARVARD BIOSCIENCE INC (HBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm EXHIBIT 99.1 Exhibit 99.1 Harvard Bioscience Announces Second Quarter 2026 Financial Results · Second Quarter 2026 Revenue Growth of 11% Year Over Year to $22.7 Million · Raises Full Year 2026 Revenue Guidance to 3%-5% Year Over Year Growth HOLLISTON, Mass.,

SEC EDGAR 8-K6 min
AUG 23
$PBRMed

Pemex and Petrobras Bet Big on High-Risk High-Reward Drilling Off Mexico

Pemex and Petrobras are collaborating to explore deep, high-risk oil prospects in the Gulf of Mexico. Pemex, facing declining production and high debt, seeks to unlock potential resources in Jurassic formations. Petrobras, with extensive pre-salt drilling experience, brings technical expertise. Success could reverse Pemex's fortunes, but risks remain high. Pemex reported a 70% net profit drop in Q2 2024, producing 1.66 million bpd, below government targets.

oilprice.com3 min